Gene Therapy Maintains Near-Normal Levels of Clotting Factor in Hemophilia B – Specialty Pharmacy Times
|
Gene Therapy Maintains Near-Normal Levels of Clotting Factor in Hemophilia B
Specialty Pharmacy Times Included in the trial were 9 adults with hemophilia B, aged 18 to 52 years. Participants were administered a single dose of an experimental gene therapy product engineered to enter the patients' liver cells and direct the production of the blood … |
